Skip to main menu Skip to main content Skip to footer

About Us
Our Therapy
Science & Technology
- Publications
Clinical
Patients
News

NT-501 Granted Orphan-Drug Designation for Macular Telangiectasia Type 2 (MacTel)

Home » NT-501 Granted Orphan-Drug Designation for Macular Telangiectasia Type 2 (MacTel)

View PDF Version

Other Posts

Media Contact

Laurie Ferguson
l.ferguson@neurotechusa.com

About Us Science & Technology Clinical Patients News Careers Publications Contact Us Supplier Code of Conduct Policy Accessibility Statement Privacy Policy Terms and Conditions of Use Policy

Stay Connected with our

and

accounts

Main Phone Number

401-333-3880

Headquarters

900 Highland Corporate Drive, Suite 101

Cumberland, RI 02864

Commercial Office

75 Second Ave, Suite 700

Needham, MA 02494

© Neurotech Pharmaceuticals, Inc. 2025

Designed by Glacial Multimedia.

⇧

Accessibility Tools

Increase Text
Decrease Text
Grayscale
High Contrast
Negative Contrast
Light Background
Links Underline
Readable Font
Reset